Human and mouse eosinophils have antiviral activity against parainfluenza virus

American Journal of Respiratory Cell and Molecular Biology

Volumn 55, Issue 3, 2016, Pages 387-394

  Drake, Matthew G ^a   Bivins Smith, Elizabeth R ^a   Proskocil, Becky J ^a   Nie, Zhenying ^a   Scott, Gregory D ^b   Lee, James J ^c   Lee, Nancy A ^c   Fryer, Allison D ^a   Jacoby, David B ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

Asthma; Eosinophil; Nitric oxide; Parainfluenza virus; Toll like receptor 7

Indexed keywords

EOSINOPHIL GRANULE PROTEIN; EOSINOPHIL PEROXIDASE; FLUORESCENT DYE; GAMMA INTERFERON; INTERLEUKIN 5; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; OVALBUMIN; RIBONUCLEASE; TOLL LIKE RECEPTOR 7; VIRUS RNA; ANTIVIRUS AGENT; PEROXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL ISOLATION; CLINICAL EVALUATION; CONTROLLED STUDY; EOSINOPHIL; FEMALE; HUMAN; HUMAN CELL; HUMAN PARAINFLUENZA VIRUS 1; IN VIVO STUDY; INNATE IMMUNITY; LUNG CLEARANCE; MOUSE; NONHUMAN; PARAINFLUENZA VIRUS INFECTION; RESPIRATORY EPITHELIUM; RNA VIRUS; TRANSGENIC MOUSE; VIRAL CLEARANCE; VIRUS INFECTIVITY; ANIMAL; C57BL MOUSE; ENZYMOLOGY; IMMUNOLOGY; LUNG; METABOLISM; PARAMYXOVIRINAE; PARAMYXOVIRUS INFECTION; PATHOGENICITY; PATHOLOGY; RHESUS MONKEY; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; EOSINOPHILS; FEMALE; HUMANS; INTERFERON-GAMMA; LUNG; MACACA MULATTA; MICE, INBRED C57BL; NITRIC OXIDE; OVALBUMIN; PARAMYXOVIRIDAE INFECTIONS; PARAMYXOVIRINAE; PEROXIDASE; RIBONUCLEASES; TOLL-LIKE RECEPTOR 7;

EID: 84988962135     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2015-0405OC     Document Type: Article

References (50)

1. Gibson PG. Inflammatory phenotypes in adult asthma: clinical applications. Clin Respir J 2009;3:198-206.
2. Fryer AD, Wills-Karp M. Dysfunction of M2-muscarinic receptors in pulmonary parasympathetic nerves after antigen challenge. J Appl Physiol (1985) 1991;71:2255-2261.
3. Kariyawasam HH, Robinson DS. The role of eosinophils in airway tissue remodelling in asthma. Curr Opin Immunol 2007;19:681-686.
4. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID; SIRIUS Investigators. Oral glucocorticoidsparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014;371:1189-1197.
5. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, et al.; MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198-1207.
6. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O?Brien C, Korn S. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015;3:355-366.
7. Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, Haahtela T, Hurd SS, Inoue H, de Jongste JC, et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J 2015; 46:622-639.
8. Zeiger RS, Schatz M, Dalal AA, Qian L, Chen W, Ngor EW, Suruki RY, Kawatkar AA. Utilization and costs of severe uncontrolled asthma in a managed-care setting. J Allergy Clin Immunol Pract 2016;4:120-129.e3.
9. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, Boulet LP. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 2012;12: 204.
10. Braman SS. The global burden of asthma. Chest 2006; 130(1, Suppl) 4S-12S.
11. Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol 2011;128:1165-1174.
12. Phipps S, Lam CE, Mahalingam S, Newhouse M, Ramirez R, Rosenberg HF, Foster PS, Matthaei KI. Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. Blood 2007;110:1578-1586.
13. Percopo CM, Dyer KD, Ochkur SI, Luo JL, Fischer ER, Lee JJ, Lee NA, Domachowske JB, Rosenberg HF. Activated mouse eosinophils protect against lethal respiratory virus infection. Blood 2014;123:743-752.
14. Adamko DJ, Yost BL, Gleich GJ, Fryer AD, Jacoby DB. Ovalbumin sensitization changes the inflammatory response to subsequent parainfluenza infection. Eosinophils mediate airway hyperresponsiveness, M2 muscarinic receptor dysfunction, and antiviral effects. J Exp Med 1999;190:1465-1478.
15. Nagase H, Okugawa S, Ota Y, Yamaguchi M, Tomizawa H, Matsushima K, Ohta K, Yamamoto K, Hirai K. Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J Immunol 2003;171:3977-3982.
16. Diebold SS. Recognition of viral single-stranded RNA by Toll-like receptors. Adv Drug Deliv Rev 2008;60:813-823.
17. Domachowske JB, Dyer KD, Bonville CA, Rosenberg HF. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis 1998;177:1458-1464.
18. Domachowske JB, Dyer KD, Adams AG, Leto TL, Rosenberg HF. Eosinophil cationic protein/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity. Nucleic Acids Res 1998;26: 3358-3363.
19. Acharya KR, Ackerman SJ. Eosinophil granule proteins: form and function. J Biol Chem 2014;289:17406-17415.
20. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, Symington P, O?Toole S, Myint SH, Tyrrell DA, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995;310:1225-1229.
21. Papadopoulos NG, Christodoulou I, Rohde G, Agache I, Almqvist C, Bruno A, Bonini S, Bont L, Bossios A, Bousquet J, et al. Viruses and bacteria in acute asthma exacerbations-a GA? LEN-DARE systematic review. Allergy 2011;66:458-468.
22. CDC. Asthma Faststats. 2015 [updated 2016 Feb 10; accessed 2016 Feb 14]. Available from: www.cdc.gov/nchs/fastats/asthma.htm
23. Lee JJ, McGarry MP, Farmer SC, Denzler KL, Larson KA, Carrigan PE, Brenneise IE, Horton MA, Haczku A, Gelfand EW, et al. Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. J Exp Med 1997; 185:2143-2156.
24. Lee JJ, Dimina D, Macias MP, Ochkur SI, McGarry MP, O?Neill KR, Protheroe C, Pero R, Nguyen T, Cormier SA, et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science 2004; 305:1773-1776.
25. Denzler KL, Borchers MT, Crosby JR, Cieslewicz G, Hines EM, Justice JP, Cormier SA, Lindenberger KA, Song W, Wu W, et al. Extensive eosinophil degranulation and peroxidase-mediated oxidation of airway proteins do not occur in a mouse ovalbumin-challenge model of pulmonary inflammation. J Immunol 2001;167:1672-1682.
26. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol 1938;27:493-497.
27. Dyer KD, Percopo CM, Fischer ER, Gabryszewski SJ, Rosenberg HF. Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6. Blood 2009; 114:2649-2656.
28. Franke-Ullmann G, Pförtner C, Walter P, Steinmüller C, Lohmann-Matthes ML, Kobzik L, Freihorst J. Alteration of pulmonary macrophage function by respiratory syncytial virus infection in vitro. J Immunol 1995;154:268-280.
29. Cheung CY, Poon LL, Ng IH, Luk W, Sia SF, Wu MH, Chan KH, Yuen KY, Gordon S, Guan Y, et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J Virol 2005;79: 7819-7826.
30. Cassidy LF, Lyles DS, Abramson JS. Synthesis of viral proteins in polymorphonuclear leukocytes infected with influenza A virus. J Clin Microbiol 1988;26:1267-1270.
31. Tao T, Ryan KW. Host range restriction of parainfluenza virus growth occurs at the level of virus genome replication. Virology 1996;220: 69-77.
32. Blair CD, Brennan PJ. Effect of Sendai virus infection on lipid metabolism in chick embryo fibroblasts. J Virol 1972;9:813-822.
33. Yu WC, Chan RW, Wang J, Travanty EA, Nicholls JM, Peiris JS, Mason RJ, Chan MC. Viral replication and innate host responses in primary human alveolar epithelial cells and alveolar macrophages infected with influenza H5N1 and H1N1 viruses. J Virol 2011;85:6844-6855.
34. Stark JM, Khan AM, Chiappetta CL, Xue H, Alcorn JL, Colasurdo GN. Immune and functional role of nitric oxide in a mouse model of respiratory syncytial virus infection. J Infect Dis 2005;191: 387-395.
35. Zanardo RC, Costa E, Ferreira HH, Antunes E, Martins AR, Murad F, De Nucci G. Pharmacological and immunohistochemical evidence for a functional nitric oxide synthase system in rat peritoneal eosinophils. Proc Natl Acad Sci USA 1997;94:14111-14114.
36. Ricciardolo FL. Multiple roles of nitric oxide in the airways. Thorax 2003; 58:175-182.
37. Saura M, Zaragoza C, McMillan A, Quick RA, Hohenadl C, Lowenstein JM, Lowenstein CJ. An antiviral mechanism of nitric oxide: inhibition of a viral protease. Immunity 1999;10:21-28.
38. Gow AJ, Farkouh CR, Munson DA, Posencheg MA, Ischiropoulos H. Biological significance of nitric oxide-mediated protein modifications. Am J Physiol Lung Cell Mol Physiol 2004;287: L262-L268.
39. Xu W, Zheng S, Dweik RA, Erzurum SC. Role of epithelial nitric oxide in airway viral infection. Free Radic Biol Med 2006;41:19-28.
40. Thomazzi SM, Ferreira HH, Conran N, De Nucci G, Antunes E. Role of nitric oxide on in vitro human eosinophil migration. Biochem Pharmacol 2001;62:1417-1421.
41. Beauvais F, Michel L, Dubertret L. The nitric oxide donors, azide and hydroxylamine, inhibit the programmed cell death of cytokinedeprived human eosinophils. FEBS Lett 1995;361:229-232.
42. Beauvais F, Joly F. Effects of nitric oxide on the eosinophil survival in vitro: a role for nitrosyl-heme. FEBS Lett 1999;443:37-40.
43. Jiao J, Wang H, Lou W, Jin S, Fan E, Li Y, Han D, Zhang L. Regulation of ciliary beat frequency by the nitric oxide signaling pathway in mouse nasal and tracheal epithelial cells. Exp Cell Res 2011;317: 2548-2553.
44. Belvisi MG, Stretton D, Barnes PJ. Nitric oxide as an endogenous modulator of cholinergic neurotransmission in guinea-pig airways. Eur J Pharmacol 1991;198:219-221.
45. Wu W, Samoszuk MK, Comhair SA, Thomassen MJ, Farver CF, Dweik RA, Kavuru MS, Erzurum SC, Hazen SL. Eosinophils generate brominating oxidants in allergen-induced asthma. J Clin Invest 2000; 105:1455-1463.
46. Klebanoff SJ, Coombs RW. Virucidal effect of stimulated eosinophils on human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1996;12:25-29.
47. Ramalingam T, Porte P, Lee J, Rajan TV. Eosinophils, but not eosinophil peroxidase or major basic protein, are important for host protection in experimental Brugia pahangi infection. Infect Immun 2005;73:8442-8443.
48. Zabucchi G, Soranzo MR, Menegazzi R, Vecchio M, Knowles A, Piccinini C, Spessotto P, Patriarca P. Eosinophil peroxidase deficiency: morphological and immunocytochemical studies of the eosinophil-specific granules. Blood 1992;80:2903-2910.
49. Linch SN, Danielson ET, Kelly AM, Tamakawa RA, Lee JJ, Gold JA. Interleukin 5 is protective during sepsis in an eosinophil-independent manner. Am J Respir Crit Care Med 2012;186:246-254.
50. Wenzel SE. Complex phenotypes in asthma: current definitions. Pulm Pharmacol Ther 2013;26:710-715.